One day after announcing a sizable acquisition, Denmark-based biotech (NASDAQ: GMAB) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the company, helping push it to a nearly 5% price gain in late-session trading. That figure was many times higher than the marginal (0.1%) rise of the S 500 (SNPINDEX: ^GSPC) at that point.

Genmab has been in the spotlight following its announcement Monday that it agreed to acquire Netherlands-headquartered peer Merus. The price is $97 per share, which is to be paid in cash. All told, the deal is valued at $8 billion, and it has been approved by the boards of directors of both companies. It is expected to close in the first calendar quarter of 2026.

Image source: Getty Images.

Continue reading

Source Fool.com